Dostarlimab

Definition

A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; programmed death-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, dostarlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T-cells. PD-1, a transmembrane protein in the Ig superfamily expressed on T-cells, functions as an immune checkpoint protein that negatively regulates T-cell activation and T-cell-mediated immune responses when activated by its ligands programmed cell death receptor ligand 1 (PD-L1) or 2 (PD-L2); it plays an important role in tumor evasion from host immunity.

Also known as ANB011, DOSTARLIMAB, Dostarlimab-gxly, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, Jemperli, TSR 042, TSR-042, TSR042 — per NCIT

Also identified as

• ATC L01FF07 per RXNORM
• NCIT NCIT:C126799 per NCIT
• SCTID 1156877005 per RXNORM
• SCTID 1156880006 per RXNORM
• UNII P0GVQ9A4S5 per RXNORM

Indications